Evgen Pharma raised £10m with up to £1.0m possible through an Open Offer to fund/progress SFX-01 to key valuation inflection points that will provide a cash runway until at least mid-2023. LifeArc’s selection of SFX-01 and funding of a 300-patient Phase II/III trial in Acute Respiratory Distress Syndrome (ARDS), including COVID-19 patients, is a significant endorsement of SFX-01’s potential value, with near-term interim safety and futility data analysis expected in Q2 2021. Additionally, Evgen s ....
